A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore

BACKGROUND: Approximately 30–70% of patients who have undergone allogeneic (allo) hematopoietic stem cell transplantation (HSCT) eventually experience chronic graft-versus-host disease (cGVHD). Patients who develop steroid-refractory (SR)-cGVHD are the most severely impacted due to significant disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ong, Jian Chun Matthew, Than, Hein, Tripathi, Sandeep, Gkitzia, Christina, Wang, Xiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230805/
https://www.ncbi.nlm.nih.gov/pubmed/37259074
http://dx.doi.org/10.1186/s12962-023-00444-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230805/
https://www.ncbi.nlm.nih.gov/pubmed/37259074
http://dx.doi.org/10.1186/s12962-023-00444-w

Ejemplares similares